SCHEMBL5936235

SCHEMBL5936235

Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1CC[C@H](N2CCC2)CC1

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 13/20 0.97
INSR P06213 8/20 0.97
LCK P06239 7/20 0.97
LYN P07948 6/20 0.97
KDR P35968 6/20 0.97
FGFR1 P11362 5/20 0.97
FLT4 P35916 5/20 0.97
FLT3 P36888 5/20 0.97
ROCK2 O75116 4/20 0.97
CHEK2 O96017 4/20 0.97
CSF1R P07333 4/20 0.97
MARK3 P27448 4/20 0.97
CSNK1D P48730 4/20 0.97
BLK P51451 4/20 0.97
NEK2 P51955 4/20 0.97
LIMK1 P53667 4/20 0.97
STK3 Q13188 4/20 0.97
ROCK1 Q13464 4/20 0.97
CDC42BPA Q5VT25 4/20 0.97
MARK2 Q7KZI7 4/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5936204 1.00 IGF1R (0.97) IGF1RINSRLCKLYNKDR
SCHEMBL5936200 1.00 IGF1R (0.97) IGF1RINSRLCKLYNKDR
SCHEMBL5936264 0.98 IGF1R (1.00) IGF1RINSRLCKLYNKDR
SCHEMBL5936382 0.98 IGF1R (1.00) IGF1RINSRLCKLYNKDR
SCHEMBL5936262 0.98 IGF1R (1.00) IGF1RINSRLCKLYNKDR
SCHEMBL5936322 0.97 IGF1R (0.98) IGF1RINSRLCKLYNKDR
SCHEMBL5936306 0.97 IGF1R (0.98) IGF1RINSRLCKLYNKDR
SCHEMBL5936303 0.97 IGF1R (0.98) IGF1RINSRLCKLYNKDR
Aew-541 SCHEMBL29358691 0.93 IGF1R (1.00) IGF1RINSRLCKLYNKDR
SCHEMBL5936253 0.92 IGF1R (0.86) IGF1RINSRLCKLYNKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058324-A1 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives CAPRARO HANS-GEORG 2006-03-16 US claimed
EP-1562947-A1 4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES Novartis AG (CH) 2005-08-17 EP claimed
WO-2004043962-A1 4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2004-05-27 WO claimed
US-20060058324-A1 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives CAPRARO HANS-GEORG 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058324-A1 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives TYMP, TYMS, APRT IGF1R 3891/4885INSR 2862/4885LCK 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.